Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
Financing round led by RA Capital Management and Forge Life Science Partners, with contributions from new and existing investors Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe…
